Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163226 | 0.85 | FLT1 (0.43) | LMNATSHRSMN1; SMN2FLT1FLT4 | |
| SCHEMBL398167 | 0.85 | LMNA (0.71) | LMNATSHRKMT2ANPC1ALDH1A1 | |
| SCHEMBL7993462 | 0.84 | ALDH1A1 (0.38) | LMNATSHRSMN1; SMN2KMT2AFLT1 | |
| SCHEMBL9360736 | 0.83 | LMNA (0.50) | LMNATSHRSMN1; SMN2KMT2AFLT1 | |
| SCHEMBL1762528 | 0.83 | LMNA (0.54) | LMNATSHRSMN1; SMN2KMT2AFLT1 | |
| SCHEMBL1669579 | 0.83 | LMNA (0.74) | LMNATSHRSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL11176923 | 0.83 | CA1 (0.53) | LMNAKMT2AALDH1A1MEN1GAA | |
| SCHEMBL11222667 | 0.81 | ALDH1A1 (0.49) | LMNATSHRKMT2AALDH1A1MEN1 | |
| SCHEMBL12569837 | 0.79 | ALDH1A1 (0.47) | LMNATSHRFLT1FLT4KDR | |
| SCHEMBL17094979 | 0.79 | HSD17B10 (0.43) | LMNAKMT2AFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890375-B1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-07-28 | — | — | EP | disclosed |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-05-04 | — | — | US | disclosed |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-08-13 | — | — | US | disclosed |
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-06-09 | — | — | US | disclosed |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-10 | — | — | US | disclosed |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-24 | — | — | US | disclosed |
| CN-102282131-B | As the new benzsulfamide of calcium ion channel blockor | ABBVIE INC. (BS) | 2015-08-26 | — | — | CN | disclosed |
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | disclosed |
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8404719-B2 | Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| CN-102282131-A | Novel benzenesulfonamides as calcium channel blockers | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2382191-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010083264-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| US-4388246-A | THERMAL SPLITTING OF CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | LMNA 868/4885TSHR 1660/4885SMN1; SMN2 973/4885 |
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | LMNA 2178/4885TSHR 1772/4885SMN1; SMN2 4600/4885 |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | LMNA 2178/4885TSHR 1772/4885SMN1; SMN2 4600/4885 |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | LMNA 2178/4885TSHR 1772/4885SMN1; SMN2 4600/4885 |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | LMNA 2178/4885TSHR 1772/4885SMN1; SMN2 4600/4885 |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | LMNA 2178/4885TSHR 1772/4885SMN1; SMN2 4600/4885 |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | LMNA 868/4885TSHR 1660/4885SMN1; SMN2 973/4885 |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | LMNA 2178/4885TSHR 1772/4885SMN1; SMN2 4600/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | LMNA 868/4885TSHR 1660/4885SMN1; SMN2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.